Drug Discovery Technologies, BCC Research

• Publication date: June 2012
• Report size: 155 pages

REPORT SCOPE INTRODUCTION STUDY GOALS AND OBJECTIVES This market research report, Drug Discovery Technologies, provides an overview of the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches. The study includes information about significant pla...

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This market research report, Drug Discovery Technologies, provides an overview of the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches. The study includes information about significant players in this field of study, trends and obstacles, and other information affecting development of new products, devices, and therapies in the drug discovery sector.

REASONS FOR DOING THIS STUDY

Drug discovery is one of the main sectors in the pharmaceutical industry. Drug development in general is a billion dollar industry and is highly dependent on its research and scientific advancement. Today, the process of drug discovery has become more systematic in comparison to the more physiological approaches in previous decades. In the current drug discovery market, the drug target is identified first, followed by a search for compounds or molecular entities that can inhibit or enhance its activity. Consequently, technology has a crucial impact on identification and validation of new drug candidates.

In general, the scientific and biotechnology community has seen many breakthrough technologies in the last decade. Surprisingly, there is a big gap between the initial introduction of new platforms and their further application and commercial success. Many analysts and industry insiders are trying to understand the reasons why, in spite of technological advancement, the pharmaceutical industry does not provide more successful drugs and why certain technologies fail to advance or accelerate the drug discovery process.

It is important to note that biological and pathological conditions are very complex. Therefore, in order to understand properly the effect of a technology or platform in drug discovery application, the market should be divided into main categories such as, for example, genomics or proteomics-based approaches and their related drug discovery technologies. Each sector has its novel trends and challenges that affect the drug discovery market in general and specific segments in particular.

Market participants vary among the different niches in the drug discovery industry. There is also a clear division between technology developers, manufacturer/ suppliers, and biotech companies. Each type of market participant has a different business strategy and is affected differently by positive or negative drivers discussed in this report.

In summary, this report will highlight the main aspects, sectors, and trends in the drug discovery technologies market, the major market participants, and the current and future trends in each sector. Drivers and challenges in each segment of the industry will be discussed in detail including forecasts for the next five years.

SCOPE AND FORMAT

This report represents a current and important business tool to evaluate new commercial opportunities in the drug discovery technology market. The geographic scope of this study covers the U.S., Europe, and companies worldwide. This market is complex and consists of a number of sectors, each affected differently by scientific and technological development. The report identifies main positive and negative factors in each sector and forecasts further trends, products, and technologies in every category of the industry.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this report. The research methodology was more qualitative than quantitative in nature and employed a triangulating approach, which aids validity. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already-marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis was also conducted.

In a second phase, a series of semi-structured interviews was conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotech and pharmaceutical companies. Other resources included academic institutions and technology and consulting companies. These were a rich source of data. Subsequent analysis of the documents and interview notes was iterative.

INTENDED AUDIENCE

This report is intended for business development professionals, entrepreneurs and other investment groups in order to fully understand and properly evaluate each segment in the drug discovery technology market. It provides a company’s corporate development department with new insight into competitors’ positions and reveals new opportunities otherwise overlooked or less known to the public.

ANALYST CREDENTIALS

Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in the area of biochemistry, cell biology, and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

Global Drug Discovery And Development Industry

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
SCOPE AND FORMAT 2
METHODOLOGY AND INFORMATION SOURCES 2
INTENDED AUDIENCE 2
ANALYST CREDENTIALS 3
RELATED REPORTS 3
BCC ON-LINE SERVICES 3
DISCLAIMER 4
CHAPTER TWO: SUMMARY 5
SUMMARY 5
SUMMARY TABLE GLOBAL MARKET FOR DRUG DISCOVERY
TECHNOLOGIES AND PRODUCTS, THROUGH 2017 ($ BILLIONS) 6
SUMMARY FIGURE GLOBAL MARKET FOR DRUG DISCOVERY
TECHNOLOGIES AND PRODUCTS, 2011–2017 ($ BILLIONS) 7
CHAPTER THREE: OVERVIEW 8
INTRODUCTION 8
INTRODUCTION (CONTINUED) 9
PRECLINICAL TESTING AND SUBMISSION OF AN
INVESTIGATIONAL NEW DRUG 10
CLINICAL TRIALS 11
SUBMISSION OF NEW DRUG APPLICATION OR
BIOLOGICAL LICENSING APPLICATION 12
POST–FOOD AND DRUG ADMINISTRATION APPROVAL 13
IMPACT OF GOVERNMENT REGULATIONS AND REGULATORY
APPROVALS ON THE DRUG DISCOVERY INDUSTRY 14
NEW DRUG APPROVALS 14
TABLE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS
VERSUS APPROVAL BY THE FDA, 2006–2010 14
FIGURE 1 NEW MOLECULAR ENTITY (NME) APPLICATIONS
VERSUS APPROVAL BY THE FDA, 2006–2010 14
New Drug Approvals (Continued) 15
TIMELINE AND COSTS 16
FIGURE 2 TIMELINE FOR DRUG DEVELOPMENT PROCESS 16
TABLE 2 FACTS ABOUT DRUG DISCOVERY AND DEVELOPMENT
FOR 2010 17
TABLE 3 R&D SPENDING FOR DRUG DISCOVERY IN
BIOPHARMACEUTICAL COMPANIES, 2008–2012 ($ MILLIONS) 17
IMPORTANCE OF TECHNOLOGY IN DRUG DISCOVERY 18
MARKET LANDSCAPE IN THE DRUG DISCOVERY SECTOR 19
TABLE 4 FDA-APPROVED DRUGS FOR SALE IN THE U S 2001-2011 20
TABLE 5 GLOBAL PHARMACEUTICAL MARKET VALUE, THROUGH
2017 ($ BILLIONS) 21
MARKET PARTICIPANTS IN THE DRUG DISCOVERY
SECTOR 21
TABLE 6 TOP GLOBAL PHARMACEUTICAL CORPORATION
RANKING, 2009 22
TABLE 7 NUMBER OF DEALS AND THEIR VALUE IN THE
PHARMACEUTICAL INDUSTRY IN DIFFERENT COUNTRIES,
2010 23
PATENTS AND DRUG DISCOVERY TECHNOLOGY 23
PATENTS AND DRUG DISCOVERY … (CONTINUED) 24
PATENTS AND DRUG DISCOVERY … (CONTINUED) 25
TABLE 8 PATENT APPLICATION IN DRUG DISCOVERY FROM
MARCH 2012 26
TABLE 8 (CONTINUED) 27
CHAPTER FOUR: GENOMICS RESEARCH AND DRUG DISCOVERY
TECHNOLOGIES 28
OVERVIEW 28
GENOMICS STUDIES AS A PLATFORM FOR DRUG DISCOVERY
TECHNOLOGIES 29
POLYMERASE CHAIN REACTION TECHNOLOGY AS BASIS
FOR DRUG DISCOVERY 30
TABLE 9 GLOBAL REAL-TIME POLYMERASE CHAIN REACTION
MARKET, THROUGH 2017 ($ BILLIONS) 31
DNA MICROARRAYS AND DRUG DEVELOPMENT 32
DNA Microarrays and Drug Development (Continued) 33
TABLE 10 GLOBAL MARKET FOR DNA MICROARRAYS, THROUGH
2017 ($ BILLIONS) 34
RNA RESEARCH AS DRUG DISCOVERY PLATFORM FOR
NEW TECHNOLOGIES DEVELOPMENT 35
RNA Research as Drug Discovery … (Continued) 36
RNA Interference as Approach to Drug Discovery 37
TABLE 11 GLOBAL RNA INTERFERENCE MARKET, THROUGH 2017
($ MILLIONS) 38
Market Participants in the Drug Discovery Sector 38
Market Participants … (Continued) 39
NEXT-GENERATION SEQUENCING AS A TECHNOLOGY
FOR DRUG DISCOVERY RESEARCH 40
Next-Generation Sequencing … (Continued) 41
TABLE 12 GLOBAL NEXT-GENERATION SEQUENCING MARKET,
THROUGH 2017 ($ MILLIONS) 42
Next-Generation Sequencing Market Participants 43
Next-Generation … (Continued) 44
TABLE 13 NEXT-GENERATION SEQUENCING MARKET SHARES BY
COMPANY, 2012 (%) 45
EPIGENETICS APPROACH AS A PLATFORM FOR DRUG
DISCOVERY 45
DNA METHYLATION 46
HISTONE METHYLATIONS AND MODIFICATIONS 47
TABLE 14 PERCENTAGE OF COMMERCIAL KITS GENERALLY
PURCHASED FOR EPIGENETIC RESEARCH (%) 48
Market Evaluation for Drug Discovery in Epigenetics
Research 48
TABLE 15 GLOBAL MARKET FOR RESEARCH AND DRUG
DISCOVERY IN EPIGENTICS, THROUGH 2017 ($ BILLIONS) 49
TABLE 16 SALES OF FOUR EPIGENETIC DRUGS, 2009–2011 ($
MILLIONS) 50
SUMMARY AND EVALUATION OF GENOMICS-BASED DRUG
DISCOVERY TECHNOLOGY MARKET 51
TABLE 17 GLOBAL MARKET FOR GENOMICS-BASED DRUG
DISCOVERY PLATFORMS, THROUGH 2017 ($ BILLIONS) 51
CHAPTER FIVE: PROTEOMICS RESEARCH AS A DRUG DISCOVERY
TECHNOLOGY AND PLATFORM 52
OVERVIEW 52
PROTEOMICS TECHNOLOGIES THE IN DRUG DISCOVERY
MARKET 53
PROTEIN ISOLATION AND IDENTIFICATION
TECHNOLOGY FOR BIOMARKER OR DRUG TARGET
DISCOVERY 53
Size Exclusion Chromatography 54
Separation Based on Charge or Hydrophobicity 54
Affinity Chromatography 55
Immunoaffinity Chromatography 55
High-Performance Liquid Chromatography as One of the
Main Technologies in Proteomics Drug Discovery 55
High-Performance Liquid (Continued) 56
Sample Injectors 57
Pumps 57
Columns 57
TABLE 18 GLOBAL HIGH-PERFORMANCE (OR HIGH-PRESSURE)
LIQUID CHROMATOGRAPHY (HPLC) MARKET, THROUGH 2017 ($
BILLIONS) 58
TABLE 19 PERCENTAGE OF CUSTOMER DISTRIBUTION IN
COLUMN SEPARATION MARKET IN 2011 59
PROTEIN IDENTIFICATION AND CHARACTERIZATION
TECHNIQUES IN PROTEOMICS DRUG DISCOVERY 59
Mass Spectrometry and the Drug Discovery Sector 59
Mass Spectrometry Instruments 60
Ionization Procedure 60
Matrix-Assisted Laser Desorption/Ionization
(MALDI) 61
Electrospray Ionization (ESI) 61
Atmospheric Pressure Chemical Ionization
(APCI) 61
Mass Analyzers 62
Quadrupole 62
Time-of-Flight Mass Spectrometry 62
Quadrupole—Time-of-Flight (Q-TOF) 63
Ion Trap Mass Spectroscopy 63
Orbitrap 64
TABLE 20 EXAMPLES OF MASS SPECTROMETRY ANALYZERS
USED IN THE PHARMACEUTICAL INDUSTRY 65
Market Overview for Mass Spectrometry 65
TABLE 21 GLOBAL MASS SPECTROMETRY MARKET, THROUGH
2017 ($ BILLIONS) 65
Main Players in Mass Spectrometry Industry 66
NMR (NUCLEAR MAGNETIC RESONANCE) APPROACH IN
PROTEOMICS DRUG DISCOVERY 67
TABLE 22 PERCENTAGE OF TOTAL NUCLEAR MAGNETIC
RESONANCE (NMR) APPLICATIONS IN VARIOUS SECTORS (%) 68
TABLE 23 GLOBAL NUCLEAR MAGNETIC RESONANCE (NMR)
MARKET, THROUGH 2017 ($ MILLIONS) 68
X-RAY CRYSTALLOGRAPHY 69
X-Ray Crystallography (Continued) 70
TWO-DIMENSIONAL GEL APPROACH AS A TECHNOLOGY
IN PROTEOMICS DRUG DISCOVERY 71
TABLE 24 GLOBAL MARKET FOR TWO-DIMENSIONAL (2D) GEL
ANALYSIS, THROUGH 2017 ($ MILLIONS) 71
Two-Dimensional Gel Approach … (Continued) 72
PROTEIN-PROTEIN INTERACTION IDENTIFICATION
TECHNIQUES IN DRUG DISCOVERY 73
PROTEIN MICROARRAYS AS PART OF A DRUG
DISCOVERY PLATFORM 74
TABLE 25 GLOBAL PROTEIN CHIP MARKET, THROUGH 2017 ($
MILLIONS) 75
Protein Microarrays …(Continued) 76
PROTEOMICS-BASED DRUG DISCOVERY MARKET LANDSCAPE 77
TABLE 26 PROTEOMICS MARKET PARTICIPANTS BY INDUSTRY
SEGMENT 77
PROTEOMICS-BASED … (CONTINUED) 78
TABLE 27 GLOBAL PROTEOMICS DRUG DISCOVERY TECHNOLOGY
MARKET, THROUGH 2017 ($ BILLIONS) 79
PROTEOMICS-BASED … (CONTINUED) 80
CHAPTER SIX: METABOLOMICS AS DRUG DISCOVERY PLATFORM 81
OVERVIEW 81
GENERAL TECHNIQUES AND METHODS FOR
METABOLITE PROFILING 81
METABOLOMICS APPLICATIONS AND DRUG DISCOVERY 82
Market Evaluation for Metabolomic Application 83
TABLE 28 GLOBAL MARKET FOR METABOLOMICS APPLICATIONS,
THROUGH 2017 ($ MILLIONS) 84
NEW TECHNOLOGICAL PLATFORMS 84
FURTHER DEVELOPMENT OF BIOINFORMATICS AND
CHEMOMETRICS STUDIES 84
Market Participants in the Metabolomics Industry 85
TABLE 29 SELECT MARKET PARTICIPANTS IN THE
METABOLOMICS MARKET 85
Market Participants … (Continued) 86
Market Participants … (Continued) 87
CHAPTER SEVEN: HIGH-THROUGHPUT SCREENING IN DRUG
DISCOVERY 88
OVERVIEW 88
HIGH-CONTENT SCREENING AS HIGH-IMPACT SECTOR
OF THE HIGH-THROUGHPUT SCREENING INDUSTRY 89
High-content Screening … (Continued) 90
TABLE 30 GLOBAL MARKET FOR HIGH-THROUGHPUT
SCREENING APPROACH IN DRUG DISCOVERY, THROUGH 2017
($ BILLIONS) 91
Positive and Negative Drivers Affecting the High-
Throughput Screening Market for Drug Discovery 91
TABLE 31 GEOGRAPHICAL DISTRIBUTION OF HIGHTHROUGHPUT
SCREENING MARKET USERS FOR 2012 (%) 92
TABLE 32 EFFECT OF NANODROP TECHNOLOGY ON COSTS IN
TYPICAL LUMINESCENCE ASSAYS 93
TABLE 33 MAIN MARKET PROVIDERS IN HIGH-THROUGHPUT
SCREENING IN 2012 94
CHAPTER EIGHT: BIOINFORMATICS AS A PLATFORM FOR DRUG
DISCOVERY 95
OVERVIEW 95
OVERVIEW (CONTINUED) 96
TABLE 34 GLOBAL MARKET FOR BIOINFORMATICS PRODUCTS
THROUGH 2017 ($ BILLIONS) 97
HARDWARE, INSTRUMENTS AND SOFTWARE
DEVELOPMENT 97
DATABASE AND CONTENT PRODUCTS AND SERVICES 97
DATA MANAGEMENT AND STORAGE 98
MARKET LANDSCAPE IN BIOINFORMATICS INDUSTRY FOR
DRUG DISCOVERY 98
TABLE 35 FREE MAJOR ONLINE SOURCES OF GENOMIC AND
PROTEOMIC INFORMATION 99
TABLE 36 EXAMPLE OF ANNUAL REVENUES OF SOME MARKET
PARTICIPANTS IN THE BIOINFORMATICS MARKET FOR DRUG
DISCOVERY, 2009-2011 ($ MILLIONS) 100
MARKET LANDSCAPE IN … (CONTINUED) 101
CHAPTER NINE: CELLULAR ASSAYS AS TECHNOLOGY AND
PLATFORM FOR DRUG DISCOVERY 102
OVERVIEW 102
TABLE 37 GLOBAL SHARES OF CELL-BASED ASSAYS MARKET BY
CATEGORY, 2012 (%) 102
G-PROTEIN COUPLED RECEPTORS (GPCR) AS A TARGET
FOR CELL-BASED ASSAY DEVELOPMENT IN THE
DRUG DISCOVERY INDUSTRY 103
ION CHANNELS AS TARGETS FOR CELL-BASED ASSAY
DEVELOPMENT 104
Cell-Based Kinase Assays 104
Cell-Based … (Continued) 105
TABLE 38 GLOBAL MARKET SHARES OF CELL BIOLOGY
REAGENTS BY PRODUCT CATEGORY (%) 106
TABLE 39 GLOBAL MARKET FOR CELL BIOLOGY REAGENTS,
THROUGH 2017 ($ BILLIONS) 106
Light Microscopy 107
Fluorescent Microscopy 107
Confocal Microscopy 107
Electron Microscopy 108
TABLE 40 GLOBAL MARKET FOR CELL-BASED ASSAYS FOR DRUG
DISCOVERY, THROUGH 2017 ($ BILLIONS) 108
MARKET PARTICIPANTS IN THE CELL-BASED DRUG
DISCOVERY MARKET 109
MARKET PARTICIPANTS IN THE … (CONTINUED) 110
TABLE 41 EXAMPLES OF STEM CELL RESEARCH ASPECTS THAT
REQUIRE DEVELOPMENT OF SPECIFIC RESEARCH TOOLS,
ASSAYS AND SERVICES 111
TABLE 42 SELECT REAGENTS PROVIDERS FOR STEM CELL
RESEARCH AND DRUG DISCOVERY 112
TABLE 42 (CONTINUED) 113
TABLE 43 EXAMPLES OF STEM CELL POLICIES IN DIFFERENT
COUNTIES 114
TABLE 43 (CONTINUED) 115
CHAPTER TEN: COMBINATORIAL AND MEDICINAL CHEMISTRY AS A
TECHNOLOGY AND PLATFORM FOR DRUG DISCOVERY 116
OVERVIEW 116
OVERVIEW (CONTINUED) 117
COMBINATORIAL CHEMISTRY TECHNOLOGY 118
COMBINATORIAL CHEMISTRY …(CONTINUED) 119
NATURE AS A SOURCE OF DRUGS 120
MARKET ESTIMATES FOR COMBINATORIAL CHEMISTRY 120
TABLE 44 GLOBAL MARKET FOR COMBINATORIAL CHEMISTRY IN
DRUG DISCOVERY, THROUGH 2017 ($ BILLIONS) 121
CHAPTER ELEVEN: BIOANALYTICAL INSTRUMENTS IN THE DRUG
DISCOVERY SECTOR 122
OVERVIEW 122
TABLE 45 GLOBAL MARKET FOR BIOANALYTICAL INSTRUMENTS
IN DRUG DISCOVERY, THROUGH 2017 ($ BILLIONS) 123
CHAPTER TWELVE: NOVEL AND INNOVATIVE TRENDS IN DRUG
DISCOVERY TECHNOLOGY DEVELOPMENT 124
SYNTHETIC BIOLOGY IN DRUG DISCOVERY 124
SYSTEMS BIOLOGY AS DRUG DISCOVERY PLATFORM 125
TABLE 46 ESTIMATED VALUE OF SYSTEMS BIOLOGY MARKET,
THROUGH 2017 ($ MILLIONS) 126
SYSTEMS BIOLOGY AS DRUG … (CONTINUED) 127
NANOTECHNOLOGY AS A NEW ESSENTIAL TREND IN DRUG
DISCOVERY AND DEVELOPMENT 128
TABLE 47 MEDICAL PRODUCT EXAMPLES WITH FUNCTIONAL
NANOTECH COMPONENTS 129
TABLE 47 (CONTINUED) 130
TABLE 48 GLOBAL MARKET FOR NANOMEDICINE PRODUCTS,
THROUGH 2017 ($ BILLIONS) 130
NANOTECHNOLOGY AS A NEW … (CONTINUED) 131
CHAPTER THIRTEEN: MARKET SUMMARY 132
MARKET SUMMARY 132
MARKET SUMMARY (CONTINUED) 133
TABLE 49 GLOBAL MARKET FOR DRUG DISCOVERY
TECHNOLOGIES AND PRODUCTS, THROUGH 2017 ($ BILLIONS) 134
FIGURE 3 GLOBAL MARKET FOR DRUG DISCOVERY
TECHNOLOGIES AND PRODUCTS, 2011–2017 ($ BILLIONS) 134
MARKET SUMMARY (CONTINUED) 135
CHAPTER FOURTEEN: COMPANY PROFILES 136
ACCELRYS INC 136
AGILENT TECHNOLOGIES 137
ILLUMINA INC 138
ISIS PHARMACEUTICALS 139
LUMINEX CORP 140
WATERS CORP 141
WATERS CORP (CONTINUED) 142
APPENDIX: LIST OF SELECT COMPANIES REPRESENTING THE
DRUG DISCOVERY INDUSTRY 143
ACTIVE MOTIF 143
ADVANCED CELL TECHNOLOGY INC 143
AFFYMETRIX 143
ALDAGEN INC 143
ALNYLAM PHARMACEUTICALS 143
ASTRAZENECA PHARMACEUTICAL LP 144
AVIVA BIOSCIENCES CORP 144
AURORA BIOMED INC 144
BD BIOSCIENCES 144
BECKMAN COULTER INC 144
BIO-RAD LABORATORIES 144
BIOMYX TECHNOLOGY 145
BIOVISION 145
BRUKER CORP 145
BTX INSTRUMENT DIVISION 145
CALIPER LIFE SCIENCES 145
CAPRICOR INC 145
CELL BIOSCIENCES INC 146
CELLCENTRIC LTD 146
CELGENE CORP 146
CEPHEID 146
CERES NANOSCIENCES 146
CHEMBRIDGE CORP 146
CHEMDIV 147
CHENOMX 147
CLONTECH LABORATORIES 147
COMPLETE GENOMICS INC 147
COMPUGEN LTD 147
DEVELOGEN AG 147
DIGILAB INC 148
ECHELON BIOSCIENCES INC 148
EMD4BIOSCIENCES 148
EMERALD BIOSYSTEMS 148
EPIGENTEK GROUP INC 148
EXIQON A/S 148
EVOTEC INC 149
FLUIDIGM 149
GAMIDA CELL LTD 149
GE HEALTHCARE U K LTD 149
GENECRAFT 149
GENOMATICA 149
GILSON INC 150
HIGH THROUGHPUT GENOMICS INC 150
F HOFFMAN-LA ROCHE AG 150
KINEXUS BIOINFORMATICS CORP 150
LI-COR 150
LIGON DISCOVERY 150
LIFE TECHNOLOGIES CORP 151
MARINA BIOTECH 151
MAXCYTE INC 151
METABOLON INC 151
MILLIPORE (EMD GROUP) 151
MOLECULAR DEVICES INC 151
NEURALSTEM 152
NEW ENGLAND BIOLABS 152
NEXTGEN SCIENCES INC 152
OSIRIS THERAPEUTICS INC 152
PERKIN-ELMER 152
PLURISTEM THERAPEUTICS INC 152
PROMEGA CORP 153
PROTAGEN AG 153
PROTEA BIOSCIENCES INC 153
PROTEIN DISCOVERY INC 153
PROTEOME SYSTEMS 153
QIAGEN 153
R&D SYSTEMS INC 154
SHIMADZU CORP 154
SIGMA-ALDRICH 154
STEMGENT 154
TECAN GROUP LTD 154
THERMO FISHER SCIENTIFIC INC 154
VIACYTE 155